Zacks.com on MSN4d
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug StudiesZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
study is evaluating azenosertib in combination with GSK’s GSK PARP inhibitor Zejula (niraparib) and azenosertib as monotherapy for treating PROC. The study is being conducted in partnership with ...
There's more to come in endometrial cancer as well, with RUBY Part 2 looking at the combination of Jemperli, chemo, and GSK's PARP inhibitor Zejula (niraparib), with results showing improved PFS ...
GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid suggestions it had paid too much. Now, a positive phase 3 trial for the drug will ...
The phase I/II MAMMOTH (ZN-c3-006) study is evaluating azenosertib in combination with GSK’s GSK PARP inhibitor Zejula (niraparib) and azenosertib as monotherapy for treating PROC.
A precedent for combining a PD-1/PD-L1 pathway blocker and a PARP inhibitor exists in the ANITA trial, which evaluated chemotherapy with or without atezolizumab (Tecentriq) followed by niraparib ...
GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback